<DOC>
	<DOCNO>NCT01524887</DOCNO>
	<brief_summary>The purpose study provide evidence efficacy safety support development IGIV , 10 % treatment option patient mild moderate Alzheimer´s Disease .</brief_summary>
	<brief_title>Phase 3 IGIV , 10 % Alzheimer´s Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Males female age 50 89 year inclusive time screen Written informed consent obtain either subject subject 's legally authorize representative prior studyrelated procedure Written inform consent obtain able competent caregiver willing comply requirement protocol pertain him/her , include facilitate subject 's participation study Diagnosis Probable Alzheimer´s Disease ( AD ) accord NINCDSADRDA* 1984 criterion ( * National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ) Dementia mild moderate severity ( MiniMental State Examination [ MMSE ] 1626 inclusive time screen ) Neuroimaging ( compute tomography [ CT ] MRI ) perform symptom onset consistent AD diagnosis Willingness comply requirement protocol ability comply test infusion regimen , include adequate correct visual acuity hearing ability For least 12 week prior screen , stable dos AD medication ( ) approve local regulatory authority . Subjects must two acetylcholinesterase inhibitor concurrently . Venous access repeat infusion phlebotomy If receive psychoactive medication ( eg , antidepressant monoamine oxidase inhibitor [ MAOIs ] tricyclic , antipsychotic , anxiolytic , anticonvulsant , mood stabilizer , etc . ) , must stable dos least 6 week prior screen For woman childbearing potential , subject must negative pregnancy test screening must agree employ adequate contraceptive measure ( eg , birth control pills/patches , intrauterine device , diaphragm condom [ male partner ] spermicidal jelly foam ) throughout course study For subject coronary artery stent , subject must receive documented medical clearance interventional cardiologist state subject increase risk stent occlusion immunoglobulin treatment For subject endovascular stent , subject must receive documented medical clearance vascular surgeon state subject increase risk thromboembolic event immunoglobulin treatment Main Possible AD NINCDSADRDA criterion nonAlzheimer dementia ( eg , vascular dementia , dementia Lewy body , frontotemporal dementia , dementia arise disease condition Parkinson 's disease , vitamin B12 deficiency , thyroid abnormality ) Current residence skilled nursing facility Contraindication undergo MRI ( eg , pacemaker [ exception MRIcompatible pacemaker ] , severe claustrophobia , ferromagnetic implant metal plate ) Clinically significant congestive heart failure ( eg , New York Heart Association [ NYHA ] Class III/IV symptom untreated Class II ) Current atrial fibrillation unstable angina ( angina rest ) history myocardial infarction within 12 month prior screen Uncontrolled hypertension define systolic blood pressure &gt; 160 mm Hg and/or diastolic &gt; 100 mm Hg confirm upon repeat measure History thrombosis and/or thromboembolic disease ( central peripheral ) within 12 month prior screen Known history procoagulant abnormality ( eg , factor V Leiden , antiphospholipid syndrome , protein S/protein C deficiency , AT III deficiency ) History intracerebral hemorrhage within 5 year prior screen Evidence MRI : great 4 microhemorrhages ( regardless anatomical location diagnostic characterization `` possible '' `` definite '' ) , single area superficial siderosis , vasogenic edema , macrohemorrhage , major stroke , prominent white matter disease rating score 3 agerelated white matter change ( ARWMC ) scale European Task Force ARWMC , multiple lacuna ( defined 2 lacuna great 0.5 mm size ) Head trauma loss consciousness , contusion , open head injury within 12 month prior screen Uncontrolled seizure disorder define two breakthrough seizure per year despite adequate antiepileptic drug ( AED ) treatment Modified Hachinski score &gt; 4 time screen Subjects active malignancy history malignancy within 5 year prior screen exception follow : adequately treat basal cell squamous cell carcinoma skin , carcinoma situ cervix , stable prostate cancer require treatment Active autoimmune neuroimmunologic disorder Uncontrolled major depression , psychosis , major psychiatric disorder ( ) Poorly control diabetes , define glycosylated ( glycated ) hemoglobin ( HbA1c ) ≥ 6.5 % screen Creatinine clearance &lt; 50 % normal adjusted age gender , calculate accord CockcroftGault formula , time screen Known history untreated vitamin B12 deficiency within 6 month prior screen , clinically significant abnormally low vitamin B12 time screen Abnormal clinical chemistry panel hematology panel meet one follow criterion : Serum alanine aminotransferase ( ALT ) &gt; 2.5 x upper limit normal ( ULN ) Clinically significant anemia precludes repeat blood sample hemoglobin ( Hgb ) &lt; 10.0 g/dL Absolute neutrophil count ( ANC ) &lt; 1000 cells/µL Known coagulopathy platelet count &lt; 100,000 cells/µL Total serum protein &gt; 9 g/dL Known history positive serology screen one following : hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) type 1/2 antibody Immunoglobulin A ( IgA ) deficiency ( &lt; 8 mg/dL ) Known history hypersensitivity follow infusion human blood blood component ( e.g . human immunoglobulins human albumin ) Currently receive receive : antiCD20 therapy within 12 month prior screen , immunomodulatory therapy ( e.g . antiTNF , antiIL1 , interferon ) within 12 week prior screen . The following exception allow : nonsystemic corticosteroid ( eg , topical , opthalmic inhaled glucocorticoid ) lowdose systemic corticosteroid ( prednisone &lt; 10 mg/day equivalent ) Currently receive receive intravenous subcutaneous immunoglobulin treatment within 2 year prior screen , receive immunoglobulin Baxter Protocol 160701 Currently receive receive time active immunization aim modulate AD progression Currently receive receive within 12 month prior screen investigational device , drug biologic ( eg passive immunotherapy monoclonal polyclonal antibody ) aim modulate AD progression Subject expose investigational product ( IP ) investigational device within 12 week prior screen schedule participate another clinical study involve IP investigational device course study Subject family member employee investigator The subject nursing intend begin nurse course study Any disorder disease , clinically significant abnormality laboratory clinical test ( ) ( eg , blood test , urine test , electrocardiogram , chest xray ) , medical judgment may impede subject 's participation study , pose increase risk subject , confound result study Currently receive anticoagulant agent and/or antiplatelet agent acetylsalicylic acid ( a.k.a . aspirin )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>